Glorywin Entertainment Group Inc(GWIN)
USD --+0.00%
Reward50Moderate
Risk32Moderate
📊75%Data
GWIN
+0.0 · +0.00%
USD · PINK
Glorywin Entertainment Group Inc | Healthcare
Balanced
Market Cap:54.53M
ℹ️
Reward Rating
50
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
32
Moderate
Risk Assessment
75% data coverage
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on GWIN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Glorywin Entertainment Group Inc?

is a 3D bioprinting technology research and development, anti-cancer drug research and development.

GWIN · Verdict

Moderate reward · moderate risk

GWIN stands out on volatility and balance sheet, but watch the profitability signal.

Based on 75% data coverage

GWIN · Verdict

What’s working & what to watch

Strengths 2

  • Volatility95/100

    Top decile vs peers

  • Balance sheet78/100

    Above average

Watchouts 1

  • Profitability40/100

    0% return on equity

Model-based scoring. For information only — not financial advice.

What is Glorywin Entertainment Group Inc?

is a 3D bioprinting technology research and development, anti-cancer drug research and development. The company was incorporated in 2010 and is based in Denton, Texas. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 54.53M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (50)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap54.53M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.2
52 Week Low0.102
Last AnnualMarch
IPO DateN/A
IncorporatedUSA
Shares Outstanding356M
No. of EmployeesN/A
IndustryBiotechnology
ExchangePINK
BetaN/A
CurrencyUSD